SYNCAR-001 is under clinical development by Synthekine and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin Lymphoma have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SYNCAR-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SYNCAR-001 overview
Synthekine overview
Synthekine is a biotherapeutics company focused on of novel specific, selective and potent cytokine therapies for the treatment of cancer and autoimmune disorders. The company is investigating its lead programs candidate in IND-enabling development STK-012, an engineered Interleukin-2 (IL-2) partial agonist targeting cancer, STK-009 and SYNCAR-001, an orthogonal IL-2 ligand designed to selectively activate CAR-Ts and other adoptive cell therapies (ACTs) in vivo to improve efficacy CAR-Ts and other ACTs by data evaluation. Synthekine is headquartered in Menlo Park, California, the US.
For a complete picture of SYNCAR-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
